Crescent Biopharma raises $143.7M in public offering on Nasdaq

Crescent Biopharma, Inc. (Nasdaq: CBIO) closed an underwritten public offering of ordinary shares and pre-funded warrants, raising approximately $143.7 million in gross proceeds before deducting underwriting discounts, commissions, and other expenses, according to a press release.

The clinical-stage biotechnology company sold 9,387,896 ordinary shares, including 1,293,103 shares issued through the full exercise of the underwriters' option to purchase additional shares. In lieu of ordinary shares, certain investors received pre-funded warrants to purchase up to 525,897 ordinary shares.

Ordinary shares were priced at $14.50 per share, while pre-funded warrants were sold at $14.499 each, reflecting the per-share price minus the $0.001 exercise price per warrant. All securities were sold by Crescent.

Jefferies, TD Cowen, Guggenheim Securities, and Cantor served as joint book-running managers. LifeSci Capital acted as passive book-running manager.

The offering was conducted under a shelf registration statement on Form S-3, declared effective by the Securities and Exchange Commission on July 10, 2026.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• Global Interactive Technologies receives Nasdaq non-compliance notice
• RenovoRx regains Nasdaq minimum bid price compliance